Table 4:
Patient characteristics of melanoma subgroup
| ICI (n=22) | non-ICI (n=14) | ||
|---|---|---|---|
| Age, yr | 68.5 (59.5–73.3) | 62 (54.8–75.6) | |
| Female (%) | 2 (9.1) | 4 (28.6) | |
| Time from transplant to diagnosis, yr | 7.1 (2.2–15.1) | 7.7 (3.5–15.3) | |
| Stage at advanced diagnosis (%) | IIIc (unresectable) | 5 (22.7) | 3 (21.4) |
| IV | 17 (77.2) | 11 (78.6) | |
| BRAF V600 mutation status | Mutation+ | 4 (18.2) | 5 (35.7) |
| Wild type | 18 (81.8) | 6 (42.9) | |
| Unknown | 0 (0.0) | 3 (21.4) | |
| Baseline Cr, mg/dl | 1.37 (1.03–1.71) | 1.05 (0.78–1.55) | |
| Other cancer-directed therapy (%) | 14 (58.3) | 7 (50.0) | |
| ICI | |||
| Pembrolizumab (%) | 11 (50.0) | ||
| Nivolumab (%) | 2 (9.1) | ||
| Ipilimumab (%) | 1 (4.5) | ||
| Combination (%) | 8 (36.3) | ||
| Tumor response | |||
| CR (%) | 1 (4.5) | 1 (7.1) | |
| PR (%) | 7 (31.8) | 1 (7.1) | |
| SD (%) | 1 (4.5) | 2 (14.3) | |
| PD (%) | 11 (50.0) | 10 (71.4) | |
| Unknown (%) | 2 (9.1) | 0 (0) | |
| Number of immunosuppressants (%) | |||
| 0 | 0 (0.0) | 3 (21.4) | |
| 1 | 8 (36.3) | 1 (7.1) | |
| 2 | 11 (50.0) | 8 (57.1) | |
| 3 | 3 (13.6) | 2 (14.3) | |
| Rejection (%) | 12 (54.5) | 1 (7.1) | |
| Follow-up, months | 9.7 (5.5–20.0) | 11.4 (3.3–22.4) | |
Data are shown as median (IQR) and n (%). ICI; immune checkpoint inhibitor, PD-1; programmed cell death protein 1, CTLA-4; cytotoxic T-lymphocyte-associated protein 4, CR; complete response, PR; partial response, SD; stable disease, PD; progressive disease. Other cancer-directed therapy includes chemotherapy and molecular-targeted therapy except for ICI.